Navigation Links
ArunA Biomedical Announces Co-development of Fully Validated Induced Pluripotent Stem Cell Kit
Date:3/31/2009

ATHENS, Ga., March 31 /PRNewswire/ -- ArunA Biomedical, Inc., a leader in human embryonic stem cell derived products, announced today that it has co-developed a validated kit to produce induced pluripotent stem cells with Open Biosystems now part of Thermo Fisher.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080819/CLTU003LOGO)

In the spirit of collaboration ArunA Biomedical and Open Biosystems will launch the complete and fully validated induced pluripotent stem cell (iPS) kits containing all the tools and reagents necessary to generate patient and disease specific cell lines for use in research applications in early April. The innovative viPS(TM) product offerings will include two kit formats and additional supplemental kits designed exclusively by the companies.

ArunA co-founder and CSO, Steven Stice said, "These kits are consistent with the scientific vision of our company. They exemplify ArunA's commitment to making stem cell research easier thereby enabling investigators the opportunity to make faster advances in the stem cell field. Induced pluripotent cells generated from these kits can help find cures for many genetic disorders ranging from certain types of Alzheimer's to Huntington's disease. "

The products will be marketed by Open Biosystems, now part of Thermo Fisher. For more information please visit the product website at: www.thermo.com/openbiosystems

About ArunA Biomedical

Located in Athens, Georgia, ArunA Biomedical, Inc. is a privately held biotechnology corporation dedicated to the discovery, manufacturing and commercialization of emerging new technologies in human stem cell research for use in drug discovery and basic research. ArunA is the first company to commercialize products derived from human embryonic stem cells and sees its proprietary technology as a catalyst leading to the discovery of novel therapeutic compounds, tests for neurotoxicity and breakthroughs in understanding human development and diseases. For more information, visit: www.arunabiomedical.com

This press release contains forward-looking statements regarding the company's potential impact on scientific research and collaborations with third parties. Certain conditions could alter the outcome or progress of these statements including but not limited to unexpected manufacturing issues, product performance and quality control/assurance issues. Forward- looking statements are based on the opinions, beliefs and expectations of the company or individuals quoted in the press release and the company does not assume any obligation to update these forward-looking statements if circumstances change.


'/>"/>
SOURCE ArunA Biomedical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Mesenchymal Cells
2. ArunA Biomedical, Inc. Announces Alliance with Neuromics for Distribution of Normal Human Neural Cells
3. ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Neural Cells
4. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
5. ArunA Biomedical Names William T. Sharp President and Chief Executive Officer
6. BioMedical Enterprises, Inc. (BME) Announces the Appointment of Keith M. Peeples as Vice President, Sales and Marketing
7. Collexis Connects Biomedical Researchers and Clinical Scientists with the Collexis Expert Platform for Translational Research
8. The NIHR Biomedical Research Centre for Mental Health London has Joined the MetaMiner CNS Partnership Program
9. PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009
10. Environmental Tectonics Corporations BioMedical Divisions Hyperbaric Chambers Address U.S. President Obamas Initiative to Computerize Medical Records
11. Environmental Tectonics Corporations BioMedical Division Announces Sale of Two Monoplace Hyperbaric Chambers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... LOUISVILLE, Ky. , Jan. 16, 2017  Eurofins ... service, which will allow more customers to receive their ... price premium or compromise in quality found with other ... the United States at no additional ... variety of routine genetic studies, including DNA sequencing, genotyping, ...
(Date:1/13/2017)... ... 13, 2017 , ... Two Kalamazoo entrepreneurs have launched AgTonik ... that farms, greenhouses and hydroponics operations use to increase yields and promote plant ... segments of customers using this high grade fulvic acid extracted from a mineral ...
(Date:1/12/2017)... Ca (PRWEB) , ... January ... ... low-cost, disposable devices with short response times capable of performing routine electrochemical ... fields, disposable screen-printed electrodes provide fast, sensitive detection and quantification of various ...
(Date:1/12/2017)... January 12, 2017 A new report published by Allied Market ... Global Opportunity Analysis and Industry Forecast, 2014-2022," projects that the global in vitro toxicity ... at a CAGR of 15.07% during the forecast period. ... ... ...
Breaking Biology Technology:
(Date:1/4/2017)... Jan. 4, 2017  CES 2017 – Valencell ... technology, today announced the launch of two new ... the highly-accurate biometric sensor modules that incorporate the ... experience and expertise. The two new designs include ... for hearables, and Benchmark BW2.0, a 2-LED version ...
(Date:12/22/2016)... -- SuperCom (NASDAQ:   SPCB ... Public Safety, HealthCare, and Finance sectors announced today that Leaders in ... implement and deploy a community-based supportive services program to reduce recidivism ... further expanding its presence in the state. ... This new program, which is expected to ...
(Date:12/19/2016)... España y TORONTO , 19 de diciembre de ... Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo ... varios tipos de tumor en 2017, con múltiples sitios previstos a ... ... con objetivo en el factor inhibidor de leucemia (LIF), una citoquina ...
Breaking Biology News(10 mins):